Articles related to EMERGING THERAPIES

Rodent and non-human primate studies showed glucagon and GIP agonism alone produced weight loss comparable to GLP-1-containing triple agonists in a Bluewater Biosciences-funded program.

A novel oral extended-release minoxidil formulation produced significantly greater non-vellus hair counts and patient-reported coverage improvement than placebo in men with androgenetic alopecia at six months.

A GLP-1 receptor agonist delivered directly into the knee joint received FDA Fast Track designation for osteoarthritis with synovitis, with phase 2a data not expected until 2027.

The OSPREY trial puts proximal hypoglossal nerve stimulation on the map for moderate-to-severe OSA, with strong short-term numbers and the limitations a small unblinded RCT carries.

Early trials suggest red‑light therapy may slow pediatric myopia progression, but unanswered questions around long‑term retinal safety and clinical positioning remain.

“These findings support AMPA receptors as a clinically relevant treatment target in MDD.” – Samantha Yohn, PhD, Neurocrine Biosciences, Psych Congress NP Institute, 2026